Background: Severely ill patients diagnosed with COVID-19 have an increased risk of cardiovascular complications, especially thromboembolic events (Bikdeli 2020). The overall incidence of developing venous thromboembolism (VTE) is approximately 17% in patients diagnosed with COVID-19, with a significantly higher rate …
Background: Despite access to vaccines in developed countries, COVID19 remains a nimble and persistent foe. While case counts wax and wane the virus continues to spread and mutate. The rapid development of vaccines has been helpful but the distribution across …
Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated …
I was fortunate enough to record a podcast on Rob Orman’s, Stimulus podcast on Oct 14th, 2021. We both felt it was an important enough topic that we should post it on both his and my site. The treatment of …
Background: Since the beginning of the pandemic, hundreds of trials have been performed looking at medications with the potential to be repurposed for use against COVID19. To date, no antiviral medications directed at SARS-CoV-2 have shown any convincing evidence of …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
